Elisabeth Kemter

Prof. Dr. Elisabeth Kemter

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
NKNikolai Klymiuk
Nikolai Klymiuk
ABAndreas Blutke
Andreas Blutke
AGAlexander Graf
Alexander Graf
SKSabine Krause
Sabine Krause
KBKatinka Burkhardt
Katinka Burkhardt
EWEckhard Wolf
Eckhard Wolf
Duchenne muscular dystrophy (DMD) is caused by mutations in the X-linked dystrophin (DMD) gene. The absence of dystrophin protein leads to progressive muscle weakness and wasting, disability and death. To establish a tailored large animal model of DMD, we deleted DMD exon 52 in male pig cells by gene targeting and generated offspring by nuclear transfer. DMD pigs exhibit absence of dystrophin in skeletal muscles, increased serum creatine kinase levels, progressive dystrophic changes of skeletal muscles, impaired mobility, muscle weakness and a maximum life span of 3 months due to respiratory impairment. Unlike human DMD patients, some DMD pigs die shortly after birth. To address the accelerated development of muscular dystrophy in DMD pigs when compared with human patients, we performed a genome-wide transcriptome study of biceps femoris muscle specimens from 2-day-old and 3-month-old DMD and age-matched wild-type pigs. The transcriptome changes in 3-month-old DMD pigs were in good concordance with gene expression profiles in human DMD, reflecting the processes of degeneration, regeneration, inflammation, fibrosis and impaired metabolic activity. In contrast, the transcriptome profile of 2-day-old DMD pigs showed similarities with transcriptome changes induced by acute exercise muscle injury. Our studies provide new insights into early changes associated with dystrophin deficiency in a clinically severe animal model of DMD.

1 February 2011 in Methods
Verified
Journal Article
Closed access
HFHelmut Fuchs
Helmut Fuchs
VGValérie Gailus-Durner
Valérie Gailus-Durner
TAThure Adler
Thure Adler
JAJuan Antonio Aguilar-Pimentel
Juan Antonio Aguilar-Pimentel
LBLore Becker
Lore Becker
MAMartin M. Hrabě de Angelis
Martin M. Hrabě de Angelis

1 May 2007 in Diabetes
Verified
Journal Article
Closed access
PDF file
NHNadja Herbach
Nadja Herbach
BRBirgit Rathkolb
Birgit Rathkolb
EKElisabeth Kemter
Elisabeth Kemter
LPLisa Pichl
Lisa Pichl
MKMatthias Klaften
Matthias Klaften
RWRuediger Wanke
Ruediger Wanke
The novel diabetic mouse model Munich Ins2C95S was discovered within the Munich N-ethyl-N-nitrosourea mouse mutagenesis screen. These mice exhibit a T→A transversion in the insulin 2 (Ins2) gene at nucleotide position 1903 in exon 3, which leads to the amino acid exchange C95S and loss of the A6-A11 intrachain disulfide bond. From 1 month of age onwards, blood glucose levels of heterozygous Munich Ins2C95S mutant mice were significantly increased compared with controls. The fasted and postprandial serum insulin levels of the heterozygous mutants were indistinguishable from those of wild-type littermates. However, serum insulin levels after glucose challenge, pancreatic insulin content, and homeostasis model assessment (HOMA) β-cell indices of heterozygous mutants were significantly lower than those of wild-type littermates. The initial blood glucose decrease during an insulin tolerance test was lower and HOMA insulin resistance indices were significantly higher in mutant mice, indicating the development of insulin resistance in mutant mice. The total islet volume, the volume density of β-cells in the islets, and the total β-cell volume of heterozygous male mutants was significantly reduced compared with wild-type mice. Electron microscopy of the β-cells of male mutants showed virtually no secretory insulin granules, the endoplasmic reticulum was severely enlarged, and mitochondria appeared swollen. Thus, Munich Ins2C95S mutant mice are considered a valuable model to study the mechanisms of β-cell dysfunction and death during the development of diabetes.

25 November 2020 in Xenotransplantation
Verified
Journal Article
Open access
PDF file
AHArne Hinrichs
Arne Hinrichs
EREvamaria O. Riedel
Evamaria O. Riedel
NKNikolai Klymiuk
Nikolai Klymiuk
ABAndreas Blutke
Andreas Blutke
EKElisabeth Kemter
Elisabeth Kemter
EWEckhard Wolf
Eckhard Wolf
Background: Many genetically multi‐modified donor lines for xenotransplantation have a background of domestic pigs with rapid body and organ growth. The intrinsic growth potential of porcine xeno‐organs may impair their long‐term function after orthotopic transplantation in non‐human primate models. Since growth hormone is a major stimulator of postnatal growth, we deleted its receptor (GHR‐KO) to reduce the size of donor pigs in one step.Methods: Heart weight and proteome profile of myocardium were investigated in GHR‐KO and control pigs. GHR‐KO mutations were introduced using CRISPR/Cas9 in an α1,3‐galactosyltransferase (GGTA1)‐deficient background expressing the human cluster of differentiation (hCD46) and human thrombomodulin (hTHBD) to generate quadruple‐modified (4GM) pigs.Results: At age 6 months, GHR‐KO pigs had a 61% reduced body weight and a 63% reduced heart weight compared with controls. The mean minimal diameter of cardiomyocytes was 28% reduced. A holistic proteome study of myocardium samples from the two groups did not reveal prominent differences. Two 4GM founder sows had low serum insulin‐like growth factor 1 (IGF1) levels (24 ± 1 ng/mL) and reached body weights of 70.3 and 73.4 kg at 9 months. Control pigs with IGF1 levels of 228 ± 24 ng/mL reached this weight range three months earlier. The 4GM sows showed normal sexual development and were mated with genetically multi‐modified boars. Offspring revealed the expected Mendelian transmission of the genetic modifications and consistent expression of the transgenes.Conclusion: GHR‐KO donor pigs can be used at an age beyond the steepest phase of their growth curve, potentially reducing the problem of xeno‐organ overgrowth in preclinical studies.

27 January 2014 in Transplantation
Verified
Journal Article
Closed access
AWAnnegret Wuensch
Annegret Wuensch
ABAndrea Baehr
Andrea Baehr
ABAnjan K. Bongoni
Anjan K. Bongoni
EKElisabeth Kemter
Elisabeth Kemter
ABAndreas Blutke
Andreas Blutke
NKNikolai Klymiuk
Nikolai Klymiuk
Background Among other mismatches between human and pig, incompatibilities in the blood coagulation systems hamper the xenotransplantation of vascularized organs. The provision of the porcine endothelium with human thrombomodulin (hTM) is hypothesized to overcome the impaired activation of protein C by a heterodimer consisting of human thrombin and porcine TM. Methods We evaluated regulatory regions of the THBD gene, optimized vectors for transgene expression, and generated hTM expressing pigs by somatic cell nuclear transfer. Genetically modified pigs were characterized at the molecular, cellular, histological, and physiological levels. Results A 7.6-kb fragment containing the entire upstream region of the porcine THBD gene was found to drive a high expression in a porcine endothelial cell line and was therefore used to control hTM expression in transgenic pigs. The abundance of hTM was restricted to the endothelium, according to the predicted pattern, and the transgene expression of hTM was stably inherited to the offspring. When endothelial cells from pigs carrying the hTM transgene—either alone or in combination with an aGalTKO and a transgene encoding the human CD46—were tested in a coagulation assay with human whole blood, the clotting time was increased three- to four-fold (P<0.001) compared to wild-type and aGalTKO/CD46 transgenic endothelial cells. This, for the first time, demonstrated the anticoagulant properties of hTM on porcine endothelial cells in a human whole blood assay. Conclusions The biological efficacy of hTM suggests that the (multi-)transgenic donor pigs described here have the potential to overcome coagulation incompatibilities in pig-to-primate xenotransplantation.

16 September 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TFThomas Fröhlich
Thomas Fröhlich
EKElisabeth Kemter
Elisabeth Kemter
FFFlorian Flenkenthaler
Florian Flenkenthaler
NKNikolai Klymiuk
Nikolai Klymiuk
KOKathrin A. Otte
Kathrin A. Otte
GAGeorg J. Arnold
Georg J. Arnold
Duchenne muscular dystrophy (DMD) is caused by genetic deficiency of dystrophin and characterized by massive structural and functional changes of skeletal muscle tissue, leading to terminal muscle failure. We recently generated a novel genetically engineered pig model reflecting pathological hallmarks of human DMD better than the widely used mdx mouse. To get insight into the hierarchy of molecular derangements during DMD progression, we performed a proteome analysis of biceps femoris muscle samples from 2-day-old and 3-month-old DMD and wild-type (WT) pigs. The extent of proteome changes in DMD vs. WT muscle increased markedly with age, reflecting progression of the pathological changes. In 3-month-old DMD muscle, proteins related to muscle repair such as vimentin, nestin, desmin and tenascin C were found to be increased, whereas a large number of respiratory chain proteins were decreased in abundance in DMD muscle, indicating serious disturbances in aerobic energy production and a reduction of functional muscle tissue. The combination of proteome data for fiber type specific myosin heavy chain proteins and immunohistochemistry showed preferential degeneration of fast-twitch fiber types in DMD muscle. The stage-specific proteome changes detected in this large animal model of clinically severe muscular dystrophy provide novel molecular readouts for future treatment trials.